Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2008 Aug;17(8):1225-35. doi: 10.1517/13543784.17.8.1225 .

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Author information

1
Duke University Medical Center, Neuro-Oncology Program and Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina, 27710, USA. reard003@mc.duke.edu

Abstract

BACKGROUND:

Glioblastoma multiforme (GBM), a highly invasive and vascular cancer, responds poorly to conventional cytotoxic therapy. Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis. Cilengitide is a potent alphavbeta3 and alphavbeta5 integrin inhibitor.

OBJECTIVE:

To summarize the preclinical and clinical experience with cilengitide for GBM.

METHODS:

Preclinical studies and clinical trials evaluating cilengitide for GBM were reviewed.

RESULTS/CONCLUSIONS:

Cilengitide is active and synergizes with external beam radiotherapy in preclinical GBM models. In clinical trials for recurrent GBM, single-agent cilengitide has antitumor benefits and minimal toxicity. Among newly diagnosed GBM patients, single-arm studies incorporating cilengitide into standard external beam radiotherapy/temozolomide have shown encouraging activity with no increased toxicity and have led to a planned randomized Phase III trial.

PMID:
18616418
PMCID:
PMC2832832
DOI:
10.1517/13543784.17.8.1225
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center